BLSM
BlossomHill Therapeutics, Inc.
BLSM Q2 2026 earnings
Published Sep 18, 2026
AI summary
- GAAP EPS −$8.75, down from −$5.51 a year ago.
- BlossomHill reported a net loss of $23.8 million for the second quarter of 2026.
- Operating expenses rose to $24.7 million, driven by increased clinical trial and personnel costs.
- The company successfully completed an initial public offering in August 2026, raising $168.3 million.
- Clinical progress includes FDA Fast Track designation for BH-30643 and ongoing Phase 1/2 trial enrollment.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−$8.75
Consensus not captured before release
Prior year: −$5.51
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is in the clinical stage and currently generates no revenue from product sales.
- Operating losses increased significantly compared to the same period in 2025 due to higher R&D spending.
Read original report
Source: BlossomHill Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1